Elena Casanueva-Alvarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Elena Casanueva-Alvarez has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Merino
Unidad de Excelencia Instituto de Biomedicina y Genética Molecular (IBGM) Consejo Superior de Investigaciones Científicas (CSIC) y Universidad de Valladolid (UVa) Valladolid Spain
3 shared publications - Germán Perdomo
Instituto de Biomedicina y Genética Molecular (Consejo Superior de Investigaciones Científicas-Universidad de Valladolid), 47003 Valladolid, Spain
3 shared publications - Carlos M. González-Casimiro
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
2 shared publications - Cristina M Fernandez-Diaz
IMDEA Food, CEI UAM + CSIC, Carretera de Cantoblanco 8, 28049 Madrid, Spain
2 shared publications - Irene Cózar-Castellano
Instituto de Biomedicina y Genética Molecular (Consejo Superior de Investigaciones Científicas-Universidad de Valladolid), 47003 Valladolid, Spain
2 shared publications - Ivan Quesada
Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE) Universidad Miguel Hernández de Elche Elche Spain
2 shared publications
Latest Publications
- Open Access
- 7 May 2026
- Published by Wiley in The Journal of Physiology
- Vol. 604 (12) , 4717-4744
Chronic attenuation of brain leptin signalling is associated with early metabolic dysfunction in lean rats
Brain leptin signalling plays a central role in the regulation of energy balance and glucose homeostasis, yet its contribution to early metabolic dysfunction preceding overt obesity remains uncertain. In the present study, we examined the metabolic consequences of sustained attenuation of central leptin receptor signalling in lean rats. Adult animals received chronic i.c.v. infusion of a rat‐specific leptin receptor antagonist (SLA) or vehicle for 21 days. SLA administration increased food intake with modest gains in body weight and visceral adiposity at the same time as maintaining normoleptinemia, and induced hepatic and pancreatic lipid accumulation, hyperinsulinemia, impaired glucose tolerance and hyperglucagonemia. These alterations were accompanied by hepatic glucagon resistance, as indicated by attenuated gluconeogenic gene induction and reduced CREB phosphorylation following in vivo glucagon stimulation. SLA‐infused rats also exhibited elevated circulating total and branched‐chain amino acids, reduced hepatic branched‐chain α‐ketoacid dehydrogenase activity and increased fibroblast growth factor 21 levels, consistent with disrupted glucagon–amino acid signalling. Together, these findings indicate that impaired central leptin signalling induces co‐ordinated endocrine and metabolic disturbances in the absence of obesity, supporting a role for altered central neuroendocrine regulation in the early development of metabolic dysfunction. image Key points: Chronic attenuation of brain leptin signalling is associated with early metabolic dysfunction in lean rats. Central leptin disruption leads to hyperglucagonemia, hepatic glucagon resistance and altered amino acid metabolism. Elevated fibroblast growth factor 21 levels and impaired branched‐chain amino acid catabolism reflect early liver–α‐cell axis dysregulation. This model provides insight into neuroendocrine drivers of non‐obese prediabetes.
- 7 May 2026
- Published by Wiley in The Journal of Physiology
- Vol. 604 (12) , 4717-4744
Open AccessChronic attenuation of brain leptin signalling is associated with early metabolic dysfunction in lean rats
Brain leptin signalling plays a central role in the regulation of energy balance and glucose homeostasis, yet its contribution to early metabolic dysfunction preceding overt obesity remains uncertain. In the present study, we examined the metabolic consequences of sustained attenuation of central leptin receptor signalling in lean rats. Adult animals received chronic i.c.v. infusion of a rat‐specific leptin receptor antagonist (SLA) or vehicle for 21 days. SLA administration increased food intake with modest gains in body weight and visceral adiposity at the same time as maintaining normoleptinemia, and induced hepatic and pancreatic lipid accumulation, hyperinsulinemia, impaired glucose tolerance and hyperglucagonemia. These alterations were accompanied by hepatic glucagon resistance, as indicated by attenuated gluconeogenic gene induction and reduced CREB phosphorylation following in vivo glucagon stimulation. SLA‐infused rats also exhibited elevated circulating total and branched‐chain amino acids, reduced hepatic branched‐chain α‐ketoacid dehydrogenase activity and increased fibroblast growth factor 21 levels, consistent with disrupted glucagon–amino acid signalling. Together, these findings indicate that impaired central leptin signalling induces co‐ordinated endocrine and metabolic disturbances in the absence of obesity, supporting a role for altered central neuroendocrine regulation in the early development of metabolic dysfunction. image Key points: Chronic attenuation of brain leptin signalling is associated with early metabolic dysfunction in lean rats. Central leptin disruption leads to hyperglucagonemia, hepatic glucagon resistance and altered amino acid metabolism. Elevated fibroblast growth factor 21 levels and impaired branched‐chain amino acid catabolism reflect early liver–α‐cell axis dysregulation. This model provides insight into neuroendocrine drivers of non‐obese prediabetes.
- Open Access
- 15 November 2023
- Published by Springer Nature in Diabetologia
- Vol. 67 (1) , 218-219
Correction to: Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation
- 15 November 2023
- Published by Springer Nature in Diabetologia
- Vol. 67 (1) , 218-219
Open AccessCorrection to: Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation
- Open Access
- 2 June 2022
- Published by Springer Nature in Diabetologia
Insulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation
Aims/hypothesis: Type 2 diabetes is characterised by hyperglucagonaemia and perturbed function of pancreatic glucagon-secreting alpha cells but the molecular mechanisms contributing to these phenotypes are poorly understood. Insulin-degrading enzyme (IDE) is present within all islet cells, mostly in alpha cells, in both mice and humans. Furthermore, IDE can degrade glucagon as well as insulin, suggesting that IDE may play an important role in alpha cell function in vivo. Methods: We have generated and characterised a novel mouse model with alpha cell-specific deletion of Ide, the A-IDE-KO mouse line. Glucose metabolism and glucagon secretion in vivo was characterised; isolated islets were tested for glucagon and insulin secretion; alpha cell mass, alpha cell proliferation and α-synuclein levels were determined in pancreas sections by immunostaining. Results: Targeted deletion of Ide exclusively in alpha cells triggers hyperglucagonaemia and alpha cell hyperplasia, resulting in elevated constitutive glucagon secretion. The hyperglucagonaemia is attributable in part to dysregulation of glucagon secretion, specifically an impaired ability of IDE-deficient alpha cells to suppress glucagon release in the presence of high glucose or insulin. IDE deficiency also leads to α-synuclein aggregation in alpha cells, which may contribute to impaired glucagon secretion via cytoskeletal dysfunction. We showed further that IDE deficiency triggers impairments in cilia formation, inducing alpha cell hyperplasia and possibly also contributing to dysregulated glucagon secretion and hyperglucagonaemia. Conclusions/interpretation: We propose that loss of IDE function in alpha cells contributes to hyperglucagonaemia in type 2 diabetes.
- 2 June 2022
- Published by Springer Nature in Diabetologia
Open AccessInsulin-degrading enzyme ablation in mouse pancreatic alpha cells triggers cell proliferation, hyperplasia and glucagon secretion dysregulation
Aims/hypothesis: Type 2 diabetes is characterised by hyperglucagonaemia and perturbed function of pancreatic glucagon-secreting alpha cells but the molecular mechanisms contributing to these phenotypes are poorly understood. Insulin-degrading enzyme (IDE) is present within all islet cells, mostly in alpha cells, in both mice and humans. Furthermore, IDE can degrade glucagon as well as insulin, suggesting that IDE may play an important role in alpha cell function in vivo. Methods: We have generated and characterised a novel mouse model with alpha cell-specific deletion of Ide, the A-IDE-KO mouse line. Glucose metabolism and glucagon secretion in vivo was characterised; isolated islets were tested for glucagon and insulin secretion; alpha cell mass, alpha cell proliferation and α-synuclein levels were determined in pancreas sections by immunostaining. Results: Targeted deletion of Ide exclusively in alpha cells triggers hyperglucagonaemia and alpha cell hyperplasia, resulting in elevated constitutive glucagon secretion. The hyperglucagonaemia is attributable in part to dysregulation of glucagon secretion, specifically an impaired ability of IDE-deficient alpha cells to suppress glucagon release in the presence of high glucose or insulin. IDE deficiency also leads to α-synuclein aggregation in alpha cells, which may contribute to impaired glucagon secretion via cytoskeletal dysfunction. We showed further that IDE deficiency triggers impairments in cilia formation, inducing alpha cell hyperplasia and possibly also contributing to dysregulated glucagon secretion and hyperglucagonaemia. Conclusions/interpretation: We propose that loss of IDE function in alpha cells contributes to hyperglucagonaemia in type 2 diabetes.